Andreas Mang, the CEO of Equity Healthcare, a division of Blackstone, said spending on these diabetes and weight-loss drugs, known as GLP-1 agonists, spiked 600% across Blackstone's portfolio in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback